Prophylactic therapy in haemophilia.

Forskningsoutput: TidskriftsbidragÖversiktsartikel

Standard

Prophylactic therapy in haemophilia. / Ljung, Rolf.

I: Blood Reviews, Vol. 23, Nr. 6, 2009, s. 267-274.

Forskningsoutput: TidskriftsbidragÖversiktsartikel

Harvard

APA

CBE

MLA

Vancouver

Author

Ljung, Rolf. / Prophylactic therapy in haemophilia. I: Blood Reviews. 2009 ; Vol. 23, Nr. 6. s. 267-274.

RIS

TY - JOUR

T1 - Prophylactic therapy in haemophilia.

AU - Ljung, Rolf

PY - 2009

Y1 - 2009

N2 - Clinical experience since decades and numerous retro- and, recently, also prospective studies clearly demonstrate that prophylactic treatment, albeit much more expensive, is superior to on-demand treatment regardless if outcome focus on number of joint- or life-threatening bleeds or arthropathy, evaluated by X-ray or MRI, or quality of life measured by general or hemophilia specific instruments. Optimal prophylactic treatment should be started early (primary prophylaxis) but various opinions exist on the dose and dose interval, depending on the objective of treatment in the individual patient which in turn is usually dependent on the resources in the health care system. Secondary prophylaxis, started later in childhood or in adults is beneficial but less cost-effective. This review covers proof of concept of primary prophylaxis in children and secondary prophylaxis in adults, comparisons between prophylaxis and on demand treatment as well as outcome measurers, health economics and future trends of prophylactic treatment of hemophilia.

AB - Clinical experience since decades and numerous retro- and, recently, also prospective studies clearly demonstrate that prophylactic treatment, albeit much more expensive, is superior to on-demand treatment regardless if outcome focus on number of joint- or life-threatening bleeds or arthropathy, evaluated by X-ray or MRI, or quality of life measured by general or hemophilia specific instruments. Optimal prophylactic treatment should be started early (primary prophylaxis) but various opinions exist on the dose and dose interval, depending on the objective of treatment in the individual patient which in turn is usually dependent on the resources in the health care system. Secondary prophylaxis, started later in childhood or in adults is beneficial but less cost-effective. This review covers proof of concept of primary prophylaxis in children and secondary prophylaxis in adults, comparisons between prophylaxis and on demand treatment as well as outcome measurers, health economics and future trends of prophylactic treatment of hemophilia.

U2 - 10.1016/j.blre.2009.08.001

DO - 10.1016/j.blre.2009.08.001

M3 - Review article

VL - 23

SP - 267

EP - 274

JO - Blood Reviews

JF - Blood Reviews

SN - 1532-1681

IS - 6

ER -